贝那鲁肽联合利格列汀治疗对T2DM胰岛素信号传导、促泌素、白脂素的影响  

Effects of Benaglutide Combined with Linagliptin on Insulin Signal Transduction,Secretagogue and Asprosin in Treatment of T2DM Patients

作　　者：夏冬 辛丽娟 唐宏霞 左源渊 彭一 吴嘉鸣 鲍喜静 XIA Dong;XIN Li-juan;TANG Hong-xia;ZUO Yuan-yuan;PENG Yi;WU Jia-ming;BAO Xi-jing(Outpatient Department,Zhangjiakou,Hebei 075000,China;the Second Department of Endocrinology,Zhangjiakou,Hebei 075000,China;Outpatient Department of Endocrinology and Metabolism Disease,Zhangjiakou,Hebei 075000,China;the First Department of Endocrinology,the First Hospital of Zhangjiakou City,Zhangjiakou,Hebei 075000,China)

机构地区：[1]张家口市第一医院门诊,河北张家口075000 [2]张家口市第一医院内分泌二科,河北张家口075000 [3]张家口市第一医院内分泌代谢病门诊,河北张家口075000 [4]张家口市第一医院内分泌一科,河北张家口075000

出　　处：《临床误诊误治》2022年第2期25-29,共5页Clinical Misdiagnosis & Mistherapy

基　　金：张家口市重点研发计划项目(1921081D)。

摘　　要：目的探讨贝那鲁肽联合利格列汀治疗对2型糖尿病(T2DM)胰岛素信号传导、促泌素、白脂素的影响。方法选择2019年2月—2020年12月收治的152例T2DM,根据治疗方法不同分为观察组和对照组,每组76例。对照组给予利格列汀治疗,观察组在对照组基础上给予贝那鲁肽治疗,均治疗3个月。比较两组治疗前后空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TG)、空腹胰岛素(FINs)、稳态模型胰岛素抵抗指数(HOMA-IR)、胰岛素受体底物-1(IRS-1)、胰岛素受体底物-2(IRS-2)、葡萄糖转运体-4(GLUT-4)、细胞因子信号传导抑制因子-3(SOCS-3)、促泌素、白脂素水平及不良反应发生情况。结果治疗后,两组FPG、2 h PG、HbA1c、LDL-C、TC、TG、FINs、HOMA-IR、SOCS-3、白脂素均较治疗前降低,且观察组低于对照组(P<0.05)。治疗后,两组HDL-C、IRS-1、IRS-2、GLUT-4、促泌素较治疗前升高,且观察组高于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论贝那鲁肽联合利格列汀治疗,可改善T2DM患者糖脂代谢,促进胰岛素信号传导,改善胰岛素抵抗,且安全可靠。Objective To investigate effects of Benaglutide combined with Linagliptin on insulin signal transduction,secretagogues and asprosin in treatment of patients with type 2 diabetes mellitus(T2DM).Methods A total of 152 T2DM patients admitted between February 2019 and December 2020 were selected and divided into observation group(n=76)and control group(n=76)according to different therapeutic methods.Control group was treated with Linagliptin,while observation group was added with Benaglutide on the basis of treatment for control group,and both groups were treated for 3 months.Fasting blood glucose(FPG),2 h postprandial blood glucose(2 h PG),glycosylated hemoglobin(HbA1c),low-density lipoprotein cholesterol(LDL-C),total cholesterol(TC),high-density lipoprotein cholesterol(HDL-C),triacylglycerol(TG),fasting insulin(FINs),Homeostasis model of assessment-insulin resistance(HOMA-IR),insulin receptor substrate-1(IRS-1),insulin receptor substrate-2(IRS-2),glucose transporter-4(GLUT-4),suppressor of cytokine signaling-3(SOCS-3),secretagogues,asprosin and incidence rate of adverse reactions before and after treatment were compared between two groups.Results After treatment,levels of FPG,2 h PG,HbA1c,LDL-C,TC,TG,FINs,HOMA-IR,SOCS-3 and asprosin were significantly lower than those before treatment in both groups,and the levels in observation group were significantly lower than those in control group(P<0.05).After treatment,levels of HDL-C,IRS-1,IRS-2,GLUT-4 and secretagogue were significantly higher than those before treatment in both groups,and the levels in observation group were significantly higher than those in control group(P<0.05).There was no significant difference in incidence rate of adverse reactions between two groups(P>0.05).Conclusion Benaglutide combined with Linagliptin in treatment of patients with T2DM may improve glucose and lipid metabolism,promote insulin signal transduction and improve insulin resistance with safe and reliable.

关 键 词：糖尿病 2型 贝那鲁肽 利格列汀 胰岛素受体底物-1 葡萄糖转运体-4 促泌素 白脂素 

分 类 号：R587.1[医药卫生—内分泌]